Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04158804 · ClinicalTrials.gov registry record · NA
PROcalcitonin Impact on Antibiotic Reduction, adverSe Events and AVoidable healthcarE Costs (ProSAVE): A RCT
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 700
- Enrollment target
NCT04158804: Completed NA study, sponsored by Massachusetts General Hospital.
NCT04158804 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 700 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04158804, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 700 participants
- Enrollment target
Study Summary
Trials comparing PCT-guided antibiotic algorithms to standard management show a significant reduction in antibiotic exposure without an increase in mortality or treatment failure. Despite this strong evidence from multiple studies a recent prospective multicentric interventional trial in the US fell short of demonstrating antibiotic reductions by PCT-guided antibiotic management. Amongst other limitations the authors of that study concluded that successful implementation of PCT may require closer educational oversight. As such, this study will compare effectiveness and safety of antibiotic prescription guided by a PCT-algorithm via a Stewardship Team over standard guidelines in hospitalized adult patients with suspected or confirmed LRTI (including sepsis with respiratory focus).
Interventions
- DIAGNOSTIC_TEST procalcitonin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 700 participants |
| Start Date | 2020-05-28 |
| Est. Completion | 2023-06-17 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04158804
The ClinicalTrials.gov registry entry for NCT04158804 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 700 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which procalcitonin is the first listed.
NCT04158804 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04158804 about?
NCT04158804 is a clinical study titled "PROcalcitonin Impact on Antibiotic Reduction, adverSe Events and AVoidable healthcarE Costs (ProSAVE): A RCT". Trials comparing PCT-guided antibiotic algorithms to standard management show a significant reduction in antibiotic exposure without an increase in mortality or treatment failure. Despite this strong evidence from multiple studies a recent prospective multicentric interventional trial in the US fell...
What is the current status of trial NCT04158804?
This trial is currently completed. It is a NA study. The enrollment target is 700 participants. The study started on 2020-05-28. Estimated completion is 2023-06-17.
What interventions are being tested in trial NCT04158804?
The interventions under investigation include: procalcitonin (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04158804?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.